SAMA Schultze Special Purpose Acquisition

Portuguese Health Authority Grants Clever Leaves EU-GMP Certification for Post-Harvest Cannabis Flower

Portuguese Health Authority Grants Clever Leaves EU-GMP Certification for Post-Harvest Cannabis Flower

Multinational operator has been granted EU-GMP certification by INFARMED, I.P. for the manufacturing of Cannabis Dried Flower as API and Finished Product

TOCANCIPÁ, Colombia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today that its facility in Portugal has been granted EU-GMP certification by the Portuguese Health Authority (INFARMED, I.P.) to manufacture dried cannabis flower as an active pharmaceutical ingredient and as finished product.

The EU-GMP certification is required for the registration and marketing of medicinal cannabis products in Europe and represents an important step toward broadening Clever Leaves’ ability to reach European patients with its own products. Additionally, the certification will bolster Clever Leaves’ commitment to supporting other cannabis companies in the region by providing a platform for achieving the necessary GMP standard for expansion into the European market.

Clever Leaves is one of few players in Portugal to receive EU-GMP certification for post-harvest cannabis flower in the format of API and finished product.

Andres Fajardo, Clever Leaves’ CEO, stated, “Receiving this certification and completing the rigorous process is an honor and accomplishment for Clever Leaves, from the initial design of the installations, through the qualification and validation of all equipment and processes, to the integration of the new unit’s quality procedures into the existing quality system of Clever Leaves Portugal. The fact that we were able to meet the highest of pharmaceutical standards in less than 10 months after completion of the new facility is a huge milestone for Clever Leaves and we could not be more proud of our team for their exemplary work.”

This certification marks a new milestone for the company and puts it in an advantageous position to open up new revenue streams while consolidating existing ones in the EMEA and Pacific regions.

About Clever Leaves Holdings Inc.

Clever Leaves is a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids. Its operations in Colombia and Portugal produce cannabinoid active pharmaceutical ingredients (API) and finished products ​in flower and extract form to a growing base of B2B customers around the globe. Clever Leaves aims to disrupt the traditional cannabis production industry by leveraging environmentally sustainable, ESG-friendly, industrial-scale and low-cost production methods, with the world’s most stringent pharmaceutical quality certifications. For more information, please visit 

Press Contacts:

Rich DiGregorio

KCSA Strategic Communications







Clever Leaves Commercial Inquiries:

Andrew Miller

Head of Business Development



Clever Leaves Investor Inquiries:

Cody Slach and Jackie Keshner

Gateway Group, Inc.



 



EN
09/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Schultze Special Purpose Acquisition

 PRESS RELEASE

Clever Leaves Announces Voluntary Delisting and SEC Deregistration

Clever Leaves Announces Voluntary Delisting and SEC Deregistration TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, today announced that its Board of Directors (the “Board”) determined to voluntarily delist its common shares, without par value (the “common shares”) and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the “Warrants” and together with the common shares, the “Securities”) from The Nasdaq Stock Market LLC (“Nasdaq”...

 PRESS RELEASE

Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

Clever Leaves Reports Fourth Quarter and Full Year 2023 Results - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabi...

 PRESS RELEASE

Clever Leaves and Paradise Seeds to Develop and Register Genetic Asset...

Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for...

 PRESS RELEASE

Clever Leaves Granted Australian GMP Certification for Cannabis Produc...

Clever Leaves Granted Australian GMP Certification for Cannabis Products by the Therapeutic Goods Administration (TGA) Multinational operator has been granted Australian GMP certification by the TGA for the manufacturing of cannabis products. Clever Leaves is the first and only medicinal cannabis company globally that has GMP certifications from the European Union, Colombia, Brazil and Australia. TOCANCIPÁ, Colombia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a global medicinal cannabis company, announced today that it has been granted Australia...

 PRESS RELEASE

Clever Leaves Reports Third Quarter 2023 Results

Clever Leaves Reports Third Quarter 2023 Results - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company’s Remaining Stake in Cansativa - - Updated Full Ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch